Drug-drug interactions between raltegravirand pravastatin in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 1, 2010, Pages 82-86

  Van Luin, Matthijs ^a,b   Colbers, Angela ^a   Van Ewijk Beneken Kolmer, Eleonora W J ^a   Verweij Van Wissen, Corrien P W G M ^a   Schouwenberg, Bas ^a   Hoitsma, Arjen ^a   Da Silva, Hugo G ^c,d   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Drug interactions; Dyslipidemia; Pravastatin; Raltegravir

Indexed keywords

CARBON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTIRETROVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; MIDDLE AGED;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; BLOOD CHEMICAL ANALYSIS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLIDINONES; YOUNG ADULT;

EID: 77956643278     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181d9a354     Document Type: Article

References (21)

1. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577. (Pubitemid 34218852)
2. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578. (Pubitemid 351442013)
3. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS. 2003;17:207-210. (Pubitemid 36583344)
4. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35:e111-e112.
5. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20:725-729. (Pubitemid 43884300)
6. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477-1486. (Pubitemid 47572633)
7. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV) - infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627. (Pubitemid 37100800)
8. FDA. Isentress [package insert]; Summary of Product Characteristics. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022145s004lbl.pdf. Accessed December 16, 2009.
9. Everett DW, Chando TJ, Didonato GC, et al. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19:740-748.
10. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22:1382-1384.
11. Van Luin M, Colbers A, Verwey-Van Wissen CP, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49:1220-1227.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
13. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52:3253-3258.
14. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008;47:137-140. (Pubitemid 351920602)
15. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269. (Pubitemid 46553846)
16. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2009;46:125-133. (Pubitemid 47482607)
17. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83:293-299.
18. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581. (Pubitemid 44908269)
19. Wenning LA, Nguyen B, Teppler H, et al. Pharmacokinetic/pharmacokinetic (PK/PD) analyses for raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA; Abstract O21.
20. Wenning, LA, Hwang E, Nguyen BY, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase III studies in treatment experienced HIV-infected patients following 48 weeks of treatment. Presented at: 48th Annual ICAAC/46th IDSA meeting; October 25-28, 2008; Washington, DC. Abstract H-4054.
21. McSharry J, Weng Q, Kulaway R, et al. Dose range and dose fractionation studies for raltegravir pharmacodynamics in an in vitro hollow fiber infection model system. Presented at: 10th International workshop on clinical pharmacology of HIV therapy; April 15-17, 2009; Amsterdam, The Netherlands. Abstract O-09.